Finance

Lists
Why is CLYM up 8.94%?
Dive Deeper
CLYM:NASDAQ
Climb Bio Inc
$10.60
+8.94%
(+0.87) 1D
Oct 20, 12:17:53 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLYM...
Open
$9.84
High
$10.88
Low
$9.84
Mkt. cap
608.82M
Avg. vol.
1.33M
Volume
335.49K
52-wk high
$18.33
52-wk low
$1.64
EPS
-$0.82
Beta
-0.01
Shares outstanding
57.44M
No. of employees
29
Open
$9.84
High
$10.88
Low
$9.84
Mkt. cap
608.82M
Avg. vol.
1.33M
Volume
335.49K
52-wk high
$18.33
52-wk low
$1.64
EPS
-$0.82
Beta
-0.01
Shares outstanding
57.44M
No. of employees
29
News stories
From web sources and news partners
About Climb Bio Inc
CEO-
Employees29
Founded2018
HeadquartersWellesley Hills, Massachusetts, United States
SectorBiotechnology
Websiteclimbbio.com
Analyst ratings
Based on 12 analysts giving stock ratings to CLYM in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CLYM in the last 3 months.
Highest
Current $10.60
$40.00 (+277.36%)
Average
$28.10 (+165.09%)
Lowest
$18.00 (+69.81%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Hoang
Deutsche Bank
Buy
Initiated
$28.00
+164.2%
10/20/2026
Nevin Varghese
RBC Capital
Buy
Maintained
$23.00
+117%
10/13/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$30.00
+183%
10/12/2026
Julian Harrison
BTIG
Buy
Maintained
$32.00
+201.9%
10/01/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
09/04/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$30.00
+183%
09/04/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$25.00
+135.8%
09/03/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$40.00
+277.4%
09/03/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/03/2026
Laura Chico
Wedbush
Buy
Maintained
$20.00
+88.7%
08/19/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$18.00
+69.8%
08/07/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$35.00
+230.2%
08/07/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
06/24/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
06/12/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$21.00
+98.1%
05/06/2026
Geulah Livshits
Chardan Capital
Buy
Initiated
$22.00
+107.5%
05/05/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$18.00
+69.8%
04/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.07M
13.74M
9.37M
9.71M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.82M
5.56M
5.84M
5.64M
Operating expense
14.89M
19.30M
15.21M
15.36M
Total operating expenses
14.89M
19.30M
15.21M
15.36M
Operating income
-14.89M
-19.30M
-15.21M
-15.36M
Other non operating income
-
-
-
-
EBT including unusual items
-12.89M
-17.52M
-13.72M
-13.50M
EBT excluding unusual items
-12.89M
-17.52M
-13.72M
-13.50M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.89M
-17.52M
-13.72M
-13.50M
Net profit margin
-
-
-
-
Earnings per share
-0.19
-0.26
-0.20
-0.18
Interest and investment income
2.04M
1.83M
1.51M
1.86M
Interest expense
-
-
-
-
Net interest expenses
2.04M
1.83M
1.51M
1.86M
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.86M
-19.27M
-15.17M
-15.33M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps